Neurodegenerative disease

• Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance (27 Feb 2023)
  
• Quality of Life and a Surveillant Endocannabinoid System (05 Sep 2022)
  
• Endocannabinoid Metabolism and Traumatic Brain Injury (01 Sep 2022)
  
• Cannabinoid Drugs-Related Neuroprotection as a Potential Therapeutic Tool Against Chemotherapy-Induced Cognitive Impairment (27 Aug 2022)
  
• Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition (13 Aug 2022)
  
• New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders (07 Aug 2022)
  
• The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation (05 Aug 2022)
  
• Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders (31 Jul 2022)
  
• Medicinal Cannabis and Central Nervous System Disorders (31 Jul 2022)
  
• Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty (31 Jul 2022)
  
• Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease (20 Jul 2022)